Last reviewed · How we verify
NCT04808284
Neuromodulation in COVID-19 Patients
Phase 1, PHASE2 trial testing Transcranial direct-current stimulation in COVID-19 in 60 participants. Completed in 11 October 2021.
11 October 2021
Quick facts
| Lead sponsor | D'Or Institute for Research and Education |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 60 |
| Start date | 10 August 2021 |
| Primary completion | 11 October 2021 |
| Estimated completion | 11 October 2021 |
| Sites | 1 location across Brazil |
Drugs / interventions tested
- Transcranial direct-current stimulation
- Transcranial direct-current stimulation
- Sham Transcranial direct-current stimulation
Conditions studied
- COVID-19 — all drugs for COVID-19 →
Sponsor
D'Or Institute for Research and Education
Who can join
Adults 18 to 80, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This clinical study is aimed at investigating the effects of transcranial direct current stimulation (tDCS) on COVID-19 patients not admitted to the intensive care unit. The tDCS is a non-invasive brain stimulation technique which applies a low intensity electrical current in order to modulate neuronal activity. Patients included will be submitted to a single session with active or sham tDCS, aiming to modulate prefrontal or supplementary motor area (SMA). Evaluation protocol will be performed before and after stimulation to verify the incidence of adverse events related to treatment and whether tDCS would affect measures of executive functioning, mood, anxiety, autonomic response and motor function in COVID-19 patients. We hypothesize the neuromodulation would be a safety, promising treatment to reduce possible impairments in COVID-19 patients.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Prefrontal tDCS modulates autonomic responses in COVID-19 inpatients.
Pinto TP, Inácio JC, de Aguiar E, Ferreira AS, et al · · 2023 · cited 5× · PMID 36940750 · DOI 10.1016/j.brs.2023.03.001
Verify or expand the search:
- PubMed search for NCT04808284
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for COVID-19
Currently open trials in the same condition.
- NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
- NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
- NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
- NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
- NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting
Other D'Or Institute for Research and Education trials
Trials by the same sponsor.
- NCT07372144 — Creatine and Cognitive Health in Patients With Early-stage Breast Cancer During and After Chemotherapy Treatment · Phase 3 · not yet recruiting
- NCT07074106 — TIL-Driven De-escalated Chemotherapy in Stage I-II TNBC · Phase 2 · recruiting
- NCT06725537 — Comprehensive Demographics and Clinical Profile of NSCLC Patients · not yet recruiting
- NCT06002841 — Extracellular Vesicles From Mesenchymal Cells in the Treatment of Acute Respiratory Failure · Phase 1, PHASE2 · unknown
- NCT06091384 — Inspiratory Muscle Strength Training in Post-Covid Syndrome · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04808284 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by D'Or Institute for Research and Education
- Last refreshed: 14 October 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04808284.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing